OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BRAIN$0.8058

BrainCool AB (publ)

Medical Equipment, Supplies & DistributionVerified

BrainCool operates with a strong equity base, as evidenced by a price-to-book ratio of 1.8 and a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company's liquidity position is robust, with a current ratio of 7.03, suggesting ample short-term assets to cover liabilities. However, the company's operating cash flow of -52.7 million SEK and free cash flow of -39.4 million SEK highlight significant cash outflows, primarily driven by its operating losses. Profitability metrics are underperforming relative to industry norms. BrainCool reported a net loss of 37.1 million SEK and an operating loss of 34.4 million SEK, resulting in a return on equity of -21.1% and a return on assets of -19.3%. These figures indicate that the company is not generating returns that meet the cost of capital, a concern for investors seeking value creation. The company's revenue is concentrated in a single business line focused on neuroprotection cooling systems, with no disclosed geographic diversification in the provided data. This lack of segment or geographic diversification increases exposure to market-specific risks, particularly in the healthcare equipment sector, which is subject to regulatory and reimbursement pressures. Looking ahead, BrainCool's growth trajectory is uncertain. The company has not provided specific revenue growth projections, and its historical performance shows a consistent pattern of losses. Analysts have assigned a mean price target of 1.00 SEK, with a strong buy recommendation, but the absence of a clear path to profitability raises questions about the sustainability of this outlook. Risk factors include the company's reliance on a single product line and the absence of long-term debt, which, while reducing financial leverage risk, also limits access to capital for growth initiatives. The risk assessment indicates low dilution and liquidity risks, but the company's operating cash flow and free cash flow remain negative, signaling ongoing operational challenges. Recent filings and transcripts do not reveal any material events that would significantly alter the company's risk profile or growth prospects. The absence of immediate liquidity or dilution flags is a positive, but the company's financial performance remains a key area of concern for investors.

30-day price · BRAIN(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyBrainCool AB (publ)
TickerBRAIN.ST
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. BrainCool AB (publ) develops and commercializes medical cooling systems for neuroprotection in stroke and other neurological conditions, generating revenue primarily through product sales and service contracts.

Classification. BrainCool is classified in the Healthcare Services & Equipment sector under the Medical Equipment, Supplies & Distribution industry with 92% confidence based on verified market data.

BrainCool operates with a strong equity base, as evidenced by a price-to-book ratio of 1.8 and a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company's liquidity position is robust, with a current ratio of 7.03, suggesting ample short-term assets to cover liabilities. However, the company's operating cash flow of -52.7 million SEK and free cash flow of -39.4 million SEK highlight significant cash outflows, primarily driven by its operating losses. Profitability metrics are underperforming relative to industry norms. BrainCool reported a net loss of 37.1 million SEK and an operating loss of 34.4 million SEK, resulting in a return on equity of -21.1% and a return on assets of -19.3%. These figures indicate that the company is not generating returns that meet the cost of capital, a concern for investors seeking value creation. The company's revenue is concentrated in a single business line focused on neuroprotection cooling systems, with no disclosed geographic diversification in the provided data. This lack of segment or geographic diversification increases exposure to market-specific risks, particularly in the healthcare equipment sector, which is subject to regulatory and reimbursement pressures. Looking ahead, BrainCool's growth trajectory is uncertain. The company has not provided specific revenue growth projections, and its historical performance shows a consistent pattern of losses. Analysts have assigned a mean price target of 1.00 SEK, with a strong buy recommendation, but the absence of a clear path to profitability raises questions about the sustainability of this outlook. Risk factors include the company's reliance on a single product line and the absence of long-term debt, which, while reducing financial leverage risk, also limits access to capital for growth initiatives. The risk assessment indicates low dilution and liquidity risks, but the company's operating cash flow and free cash flow remain negative, signaling ongoing operational challenges. Recent filings and transcripts do not reveal any material events that would significantly alter the company's risk profile or growth prospects. The absence of immediate liquidity or dilution flags is a positive, but the company's financial performance remains a key area of concern for investors.
Key takeaways
  • BrainCool has a strong equity position and no long-term debt, but it is experiencing significant operating and net losses.
  • The company's return on equity and return on assets are negative, indicating poor capital efficiency.
  • Revenue is concentrated in a single product line with no geographic diversification disclosed.
  • Analysts have a positive outlook with a mean price target of 1.00 SEK, but the company's path to profitability is unclear.
  • The company's liquidity position is strong, but its operating cash flow and free cash flow remain negative.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySEK
Revenue$36.2M
Gross profit$8.6M
Operating income-$34.4M
Net income-$37.1M
R&D
SG&A
D&A
SBC
Operating cash flow-$52.7M
CapEx-$6.5M
Free cash flow-$39.4M
Total assets$192.4M
Total liabilities$16.6M
Total equity$175.8M
Cash & equivalents
Long-term debt$0.00
Valuation
Market price$0.80
Market cap$315.9M
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B1.8
P/Tangible book1.8
Tangible book$175.8M
Net cash
Current ratio7.0
Debt/Equity0.0
ROA-19.3%
ROE-21.1%
Cash conversion1.4%
CapEx/Revenue-18.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricBRAINActivity
Op margin-95.1%3.9% medp25 -31.3% · p75 14.4%bottom quartile
Net margin-102.3%2.4% medp25 -30.5% · p75 11.1%bottom quartile
Gross margin23.8%46.7% medp25 28.2% · p75 63.1%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-18.1%-4.8% medp25 -11.6% · p75 -2.4%bottom quartile
Debt / equity0.0%17.9% medp25 2.7% · p75 52.2%bottom quartile
Observations
IR observations
Mean price target1.00 SEK
Median price target1.00 SEK
High price target1.00 SEK
Low price target1.00 SEK
Mean recommendation1.00 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count0.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.06 SEK
Last actual EPS-0.15 SEK
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 22:45 UTC#95258041
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 13:24 UTCJob: e41cc509